Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

78.72USD
17 May 2019
Change (% chg)

$-0.41 (-0.52%)
Prev Close
$79.13
Open
$78.37
Day's High
$79.06
Day's Low
$77.87
Volume
2,696,348
Avg. Vol
3,450,838
52-wk High
$83.81
52-wk Low
$57.50

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.61
Market Cap(Mil.): $202,676.00
Shares Outstanding(Mil.): 2,574.65
Dividend: 0.55
Yield (%): 2.79

Financials

  MRK.N Industry Sector
P/E (TTM): 24.80 54.03 55.51
EPS (TTM): 3.17 -- --
ROI: 12.55 11.89 11.59
ROE: 27.44 13.19 16.33

Merck steps up U.S. measles vaccine production with increased demand

NEW YORK Merck & Co said on Wednesday it has increased production of the measles vaccine to meet an uptick in demand in the United States in the midst of the country's biggest outbreak in 25 years.

May 01 2019

Merck steps up U.S. measles vaccine production with increased demand

NEW YORK, May 1 Merck & Co said on Wednesday it has increased production of the measles vaccine to meet an uptick in demand in the United States in the midst of the country's biggest outbreak in 25 years.

May 01 2019

Vaccine and blood thinner help drive Pfizer to quarterly earnings beat

Pfizer Inc on Tuesday reported first-quarter profit that beat Wall Street estimates and slightly raised its 2019 earnings forecast, as the company reined in costs and recorded higher sales of blood thinner Eliquis and Prevnar pneumonia vaccine.

Apr 30 2019

UPDATE 3-Vaccine and blood thinner help drive Pfizer to quarterly earnings beat

April 30 Pfizer Inc on Tuesday reported first-quarter profit that beat Wall Street estimates and slightly raised its 2019 earnings forecast, as the company reined in costs and recorded higher sales of blood thinner Eliquis and Prevnar pneumonia vaccine.

Apr 30 2019

Merck raises full-year forecasts as vaccines power profit beat

Merck & Co Inc reported higher-than-expected first-quarter profit on Tuesday on increased demand for vaccines and cancer immunotherapy Keytruda, and the U.S. drugmaker raised its 2019 earnings and revenue forecasts.

Apr 30 2019

UPDATE 3-Merck raises full-year forecasts as vaccines power profit beat

April 30 Merck & Co Inc reported higher-than-expected first-quarter profit on Tuesday on increased demand for vaccines and cancer immunotherapy Keytruda, and the U.S. drugmaker raised its 2019 earnings and revenue forecasts.

Apr 30 2019

Merck revenue up 8 pct on higher Keytruda sales

April 30 U.S. drugmaker Merck & Co Inc reported an 8 percent increase in quarterly sales on Tuesday, as sales of its blockbuster lung cancer immunotherapy Keytruda rose.

Apr 30 2019

Merck's Keytruda wins FDA approval as combination therapy for kidney cancer

The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.

Apr 22 2019

UPDATE 1-Merck's Keytruda wins FDA approval as combination therapy for kidney cancer

April 22 The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.

Apr 22 2019

Merck's Keytruda wins FDA approval as combination therapy for kidney cancer

April 22 The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.

Apr 22 2019

Earnings vs. Estimates